AR002270A1 - Clorhidrato de valaciclovir 2-[(2-amino-1,6-dihidro-6-oxo-9h-purin-9-il)metoxi]etil-l-valinato, uso para preparar un medicamento y proceso para obtener dicha forma cristalina - Google Patents

Clorhidrato de valaciclovir 2-[(2-amino-1,6-dihidro-6-oxo-9h-purin-9-il)metoxi]etil-l-valinato, uso para preparar un medicamento y proceso para obtener dicha forma cristalina

Info

Publication number
AR002270A1
AR002270A1 ARP960101082A AR10108296A AR002270A1 AR 002270 A1 AR002270 A1 AR 002270A1 AR P960101082 A ARP960101082 A AR P960101082A AR 10108296 A AR10108296 A AR 10108296A AR 002270 A1 AR002270 A1 AR 002270A1
Authority
AR
Argentina
Prior art keywords
purin
dihydro
oxo
ethyl
amino
Prior art date
Application number
ARP960101082A
Other languages
English (en)
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR002270(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of AR002270A1 publication Critical patent/AR002270A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una forma cristalina anhidra de clorhidrato 2[-(2-amino-1,6-dihidro-6-oxo-purin-9-il)metoxi]etil L-valinato(conocido como clorhidrato de valaciclovir) y a un proceso para la elaboración del mismo.
ARP960101082A 1995-01-20 1996-01-19 Clorhidrato de valaciclovir 2-[(2-amino-1,6-dihidro-6-oxo-9h-purin-9-il)metoxi]etil-l-valinato, uso para preparar un medicamento y proceso para obtener dicha forma cristalina AR002270A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative

Publications (1)

Publication Number Publication Date
AR002270A1 true AR002270A1 (es) 1998-03-11

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101082A AR002270A1 (es) 1995-01-20 1996-01-19 Clorhidrato de valaciclovir 2-[(2-amino-1,6-dihidro-6-oxo-9h-purin-9-il)metoxi]etil-l-valinato, uso para preparar un medicamento y proceso para obtener dicha forma cristalina

Country Status (40)

Country Link
US (1) US6107302A (es)
EP (1) EP0804436B1 (es)
JP (1) JP3176633B2 (es)
KR (1) KR100376074B1 (es)
CN (1) CN1049893C (es)
AP (1) AP662A (es)
AR (1) AR002270A1 (es)
AT (1) ATE302777T1 (es)
AU (1) AU702794B2 (es)
BG (1) BG63393B1 (es)
BR (1) BR9606768A (es)
CA (1) CA2210799C (es)
CY (1) CY2531B1 (es)
CZ (1) CZ297065B6 (es)
DE (1) DE69635106T2 (es)
DK (1) DK0804436T3 (es)
EA (1) EA000364B1 (es)
EE (1) EE03528B1 (es)
ES (1) ES2248806T3 (es)
FI (1) FI973063A (es)
GB (1) GB9501178D0 (es)
GE (1) GEP20001940B (es)
HR (1) HRP960024B1 (es)
HU (1) HU222993B1 (es)
IL (1) IL116831A (es)
IN (1) IN182468B (es)
IS (1) IS2268B (es)
NO (1) NO315558B1 (es)
NZ (1) NZ298851A (es)
OA (1) OA10499A (es)
PL (1) PL182175B1 (es)
RO (1) RO118693B1 (es)
RS (1) RS49518B (es)
SI (1) SI0804436T1 (es)
SK (1) SK285329B6 (es)
TR (1) TR199700656T1 (es)
UA (1) UA46001C2 (es)
UY (1) UY25779A1 (es)
WO (1) WO1996022291A1 (es)
ZA (1) ZA96449B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
DE69726255T2 (de) * 1996-01-19 2004-08-26 Glaxo Group Ltd., Greenford Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
CA2278474A1 (en) * 1997-01-17 1998-07-23 Ajinomoto Co., Inc. Novel z-valacyclovir crystals
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
EP1953162B9 (de) * 2001-02-24 2012-10-31 Boehringer Ingelheim Pharma GmbH & Co. KG Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
JP5043286B2 (ja) * 2001-09-07 2012-10-10 テバ ファーマシューティカル インダストリーズ リミティド バラシクロビル塩酸塩の結晶型
US20040197396A1 (en) * 2001-11-05 2004-10-07 Fain Helen S Anhydrous crystal form of valaciclovir hydrochloride
PL371732A1 (en) * 2001-11-14 2005-06-27 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
AU2003240213A1 (en) * 2002-06-24 2004-01-06 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
WO2004035583A1 (en) * 2002-10-16 2004-04-29 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
CA2548608A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
EP1633753A1 (en) * 2003-05-30 2006-03-15 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Novel crystalline forms of valacyclovir hydrochloride
EP1638972A2 (en) * 2003-06-02 2006-03-29 Teva Pharmaceutical Industries Limited Novel crystalline forms of valacyclovir hydrochloride
WO2005073233A1 (en) * 2004-01-21 2005-08-11 Teva Pharmaceutical Industries Ltd. Process for the preparation of valacyclovir hydrochloride
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CN1976933A (zh) * 2004-06-30 2007-06-06 特瓦制药工业有限公司 减少晶体盐酸伐昔洛韦中的残留醇的方法
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
US7846937B2 (en) * 2005-05-25 2010-12-07 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
EP3542801A1 (en) * 2007-08-17 2019-09-25 Boehringer Ingelheim International GmbH Purin derivatives for use in the treatment of fap-related diseases
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
PE20110297A1 (es) * 2008-08-15 2011-05-26 Boehringer Ingelheim Int Inhibidores de dpp-4 para la cicatrizacion de heridas
KR20110067096A (ko) 2008-09-10 2011-06-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 및 관련 상태를 치료하기 위한 병용 요법
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
BR112012012641A2 (pt) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
EP3366304B1 (en) 2010-06-24 2020-05-13 Boehringer Ingelheim International GmbH Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
WO2013010964A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013076688A1 (en) * 2011-11-25 2013-05-30 Piramal Enterprises Limited A process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
US5831075A (en) * 1993-06-10 1998-11-03 Rolabo Sl Amino acid ester of nucleoside analogues
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
AP9701058A0 (en) 1997-10-31
HRP960024B1 (en) 2005-08-31
KR19980701525A (ko) 1998-05-15
MX9705462A (es) 1997-10-31
AP662A (en) 1998-08-19
GB9501178D0 (en) 1995-03-08
IS4527A (is) 1997-07-15
UA46001C2 (uk) 2002-05-15
AU4453996A (en) 1996-08-07
PL182175B1 (pl) 2001-11-30
SK285329B6 (sk) 2006-11-03
DE69635106D1 (de) 2005-09-29
IL116831A0 (en) 1996-05-14
WO1996022291A1 (en) 1996-07-25
RO118693B1 (ro) 2003-09-30
EE03528B1 (et) 2001-10-15
EE9700175A (et) 1998-02-16
EP0804436A1 (en) 1997-11-05
OA10499A (en) 2002-04-10
CZ229497A3 (en) 1997-12-17
JP3176633B2 (ja) 2001-06-18
TR199700656T1 (xx) 1998-03-21
GEP20001940B (en) 2000-02-05
CA2210799C (en) 2008-06-10
FI973063A (fi) 1997-09-18
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
HUP9801836A3 (en) 1999-06-28
CA2210799A1 (en) 1996-07-25
NO315558B1 (no) 2003-09-22
IL116831A (en) 1998-10-30
ZA96449B (en) 1996-08-07
EA199700124A1 (ru) 1997-12-30
CY2531B1 (en) 2006-04-12
SI0804436T1 (sl) 2006-02-28
HUP9801836A2 (hu) 1999-05-28
NZ298851A (en) 1999-01-28
YU3396A (sh) 1998-12-23
HU222993B1 (hu) 2004-01-28
BR9606768A (pt) 1997-12-30
JPH11503718A (ja) 1999-03-30
NO973326D0 (no) 1997-07-18
BG101833A (en) 1998-04-30
CN1179159A (zh) 1998-04-15
PL321326A1 (en) 1997-12-08
DE69635106T2 (de) 2006-06-08
AU702794B2 (en) 1999-03-04
RS49518B (sr) 2006-10-27
IN182468B (es) 1999-04-17
CZ297065B6 (cs) 2006-08-16
EA000364B1 (ru) 1999-06-24
KR100376074B1 (ko) 2003-06-02
ES2248806T3 (es) 2006-03-16
US6107302A (en) 2000-08-22
HRP960024A2 (en) 1997-10-31
SK96597A3 (en) 1998-02-04
NO973326L (no) 1997-09-16
UY25779A1 (es) 2000-08-21
EP0804436B1 (en) 2005-08-24
IS2268B (is) 2007-07-15
FI973063A0 (fi) 1997-07-18
ATE302777T1 (de) 2005-09-15
DK0804436T3 (da) 2005-12-27

Similar Documents

Publication Publication Date Title
AR002270A1 (es) Clorhidrato de valaciclovir 2-[(2-amino-1,6-dihidro-6-oxo-9h-purin-9-il)metoxi]etil-l-valinato, uso para preparar un medicamento y proceso para obtener dicha forma cristalina
AR038430A2 (es) Derivados de parahercuamida b
ITMI931714A0 (it) Uso del taxol per la produzione di un medicamento per il trattamento delle forme cancerose
BG101422A (en) Benzoxazole derivatives as bronchodilating compounds
LT2003017A (en) Polymorphs of an epothilone analog
MX9707453A (es) Derivados de quinazolina.
UY26782A1 (es) Derivados del benzotiazol
FI104170B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten 3-amidopyratsolijohdannaisten valmistamiseksi
GT199700052A (es) Sales metanosulfonatode5-(2-4-(1,2-benzoisotiazol-3-il)-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-onadihidratadas
ATE154880T1 (de) Multifunktionelle pharmazeutische verbindungen und verfahren zu ihrer verwendung
FI980862A (fi) Kiraalisia metyylifenyylioksatsolidinoneja
AR013079A1 (es) Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
TR200000598T2 (tr) Kemik metabolizması bozukluklarının tedavisi için bir arginin mimetiği içeren peptitler, bunların üretimi ve sözkonusu bileşikleri içeren ilaçlar.
CA2046755A1 (en) /2r/-2-[di/2-propyl/phosphonylmethoxy]-3-p-toluenesulfonyloxy-1-trimethylacetoxypropane, its preparation and use
BR9608730A (pt) Uso de benzimidazóis para a produção de um medicamento para o tratamento de leucemia
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
BR0013313A (pt) Derivados substituìdos de pirrolidino-2,3,4- triona-3-oxina eficazes como antagonistas de receptores de nmda
HK1034512A1 (en) Process for the production of purine derivatives and intermediates therefor
ES2101747T3 (es) Penciclovir y famciclovir y derivados de guanina relacionados para el tratamiento de infecciones por vih-1.
MX9400165A (es) Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen.
RU94003397A (ru) Производные 2-/4-(4-азолилбутил)-1-пиперазинил/-пиримидина, способ их получения и фармацевтическая композиция на их основе
MY127470A (en) Process for the synthesis of chloropurine intermediates
FI942888A0 (fi) Menetelmä pyranyylisyaaniguanidiinijohdanaisten valmistuksessa käyttökelpoisten välituotteiden valmistamiseksi
SE9704834D0 (sv) New process
AU6248790A (en) Process for the preparation of 2-(2-furyl)ethanol amine

Legal Events

Date Code Title Description
FC Refusal